Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

0.8769 +0.0369 (+4.39%)
Streaming Delayed Price Updated: 12:53 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TScan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
TScan Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Collapse In Q2 ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings ↗
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to... 
Via Benzinga
TScan Therapeutics Inc. (NASDAQ: TCRX) Near the Top of Equities by Percentage Gain on 5/9
Via Investor Brand Network
News headline image
TScan Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
News headline image
Crude Oil Down 1%; Under Armour Earnings Top Views ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 50 points on Tuesday. The Dow traded down 0.07% to 33,593.48 while the NASDAQ fell 0.52% to 12,193.35. The S&P... 
Via Benzinga
News headline image
Why Are TScan Therapeutics Shares Are Shooting Higher Today ↗
Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics Inc (NASDAQ: TCRX) announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recog 
Via Benzinga
News headline image
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
Company to host a virtual event to discuss highlights from its Phase 1 umbrella trial of TSC-100 and TSC-101 on Wednesday, May 17, 2023, at 5:30 p.m. ET 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces CEO Transition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
Patient treated with TSC-101, the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! 
Via InvestorPlace
News headline image
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
From TScan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.